Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 3

Among the most intriguing ideas is warp drive—a concept that challenges Einstein’s Theory of Relativity by suggesting faster-than-light travel might be possible by warping space and time.

In 1994, theoretical physicist Miguel Alcubierre introduced the idea of a space-time bubble that could contract distances ahead of a spacecraft while expanding them behind it. His model, known as the Alcubierre drive, suggested a loophole in relativity that could, in theory, allow faster-than-light travel. Yet, most scientists dismissed it as impossible due to extreme energy requirements.

Not everyone was ready to abandon the idea. Joseph Agnew, an undergraduate at the University of Alabama, set out to explore whether the theory held up mathematically. “If you fulfill all the energy requirements, they can’t prove that it doesn’t work,” he stated in a university press release.

Read more | >

Year 2024 😗

Modular tiles, 3D printed using sawdust leftover from CLT production, were joined together without additional fixings to create this pavilion showcased by Japanese firm Mitsubishi Jisho Design at Dubai Design Week.

The Warp is a teahouse pavilion developed by architects Kei Atsumi and Motoya Iizawa from Mitsubishi Jisho Design’s Tokyo headquarters, along with Singapore-based Vibha Krishna Kumar from Mitsubishi Jisho Design Asia.

The project showcases a production system developed by the architecture firm called Regenerative Wood, which uses a filament made from wood waste mixed with bioplastic to 3D print building components and furniture.

Continue reading “Japanese joinery and 3D-printed wood combine to form The Warp pavilion” | >

Year 2024 In The advent of advanced architectural buildings wanting to be more sustainable we could have 3D printed wood waste buildings that are as strong as steel and even fireproof even where the glass is made from transparent wood.

The new tower would be double the height of the current record-holder—that’s also in Milwaukee.

Read more | >

Basically fungi foods can cure nearly all diseases it just requires the right mushroom for the ailment.

Bioactive compounds and metabolites in mushrooms Mushrooms in ancient healing Edible mushrooms with therapeutic potency References Further reading

Fungi have gained significant attention in the field of phytomedicine as potential natural sources of bioactive compounds and secondary metabolites. Fungi that produce visible fruiting bodies are called macrofungi. Mushrooms are edible macrofungi mainly found in rainy and snow-melting seasons.

Mushrooms form macroscopic fruiting bodies that eventually produce and disperse spores. Mushroom spores contain all the essential components that are needed to produce a new fungus. Mushrooms can exist in nature in many forms, including leathery or woody, fleshy, or sub-fleshy forms.

Mushrooms are probably the most miraculous entities because each mushroom can aid in a different way to cure each illness in the human biology. Much like cannabis is actually a cure all for so many ailments in humans so in turn are mushrooms able to do the same.

Alzheimer’s disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency for innovative treatment modalities. Psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. Nonetheless, its potential as a therapeutic avenue for AD remains largely uncharted. This comprehensive review endeavors to encapsulate the pharmacological effects of psilocybin while elucidating the existing evidence concerning its potential mechanisms contributing to a positive impact on AD. Specifically, the active metabolite of psilocybin, psilocin, elicits its effects through the modulation of the 5-hydroxytryptamine 2A receptor (5-HT2A receptor). This modulation causes heightened neural plasticity, diminished inflammation, and improvements in cognitive functions such as creativity, cognitive flexibility, and emotional facial recognition. Noteworthy is psilocybin’s promising role in mitigating anxiety and depression symptoms in AD patients. Acknowledging the attendant adverse reactions, we proffer strategies aimed at tempering or mitigating its hallucinogenic effects. Moreover, we broach the ethical and legal dimensions inherent in psilocybin’s exploration for AD treatment. By traversing these avenues, We propose therapeutic potential of psilocybin in the nuanced management of Alzheimer’s disease.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is the leading cause of dementia in the elderly population (Anonymous, 2021). It is characterized by the deposition of amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and neuroinflammation (Scheltens et al., 2021). The prevalence of dementia is expected to rise as the global population grows and ages, with projections estimating a significant increase in the number of cases (Anonymous, 2022b). In 2019, the total cost of healthcare, long-term care, and hospice services for individuals aged 65 years and older with dementia in the United States was estimated at $2.2billion, so AD imposes a substantial burden on individuals, families, society, and the economy (Anonymous, 2022a). The U.S. Food and Drug Administration (FDA) has approved seven drugs for the treatment of AD, including rivastigmine, donepezil, galantamine, memantine, memantine combined with donepezil, aducanumab and lecanemab.

Read more | >

Professor José R Penadés told the BBC that Google’s tool reached the same hypothesis that his team had – that superbugs can create a tail that allows them to move between species. In simpler terms, one can think of it as a master key that enables the bug to move from home to home.

Penadés asserts that his team’s research was unique and that the results hadn’t been published anywhere online for the AI to find. What’s more, he even reached out to Google to ask if they had access to his computer. Google assured him they did not.

Arguably even more remarkable is the fact that the AI provided four additional hypotheses. According to Penadés, all of them made sense. The team had not even considered one of the solutions, and is now investigating it further.

Read more | >

Many aspects of inflammation increase with aging in mice and humans. Transcriptomic analysis revealed that many murine anti-aging interventions produce lower levels of pro-inflammatory proteins. Here, we explore the hypothesis that different longevity interventions diminish NF-κB levels, potentially mediating some of the anti-inflammatory benefits of lifespan-extending interventions. We found that the NF-κB protein p65 is significantly downregulated in the liver of several kinds of slow-aging mice. These included both sexes of GHRKO and Snell Dwarf mutant mice, and in females only of PAPPA KO mice. P65 is also lower in both sexes of mice treated with rapamycin, canagliflozin, meclizine, or acarbose, and in mice undergoing caloric restriction. Two drugs that extend lifespan of male mice, i.e. 17α-estradiol and astaxanthin, however, did not produce lower levels of p65.

Read more | >